O. Kostek, "Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer," AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , vol.43, no.12, pp.905, 2020
Kostek, O. 2020. Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , vol.43, no.12 , 905.
Kostek, O., (2020). Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , vol.43, no.12, 905.
Kostek, OSMAN. "Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer," AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , vol.43, no.12, 905, 2020
Kostek, OSMAN. "Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer." AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , vol.43, no.12, pp.905, 2020
Kostek, O. (2020) . "Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer." AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , vol.43, no.12, p.905.
@article{article, author={OSMAN KÖSTEK}, title={Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer}, journal={AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS}, year=2020, pages={905} }